The IL-2 variant RNA-LNP proved effective in syngeneic mouse tumor models, and the anti-tumor effect was significantly enhanced in combination with RNA-LPX vaccination or PD-1/PD-L1 checkpoint inhibition. This evidence concerns the gene PDCD1 and neoplasm.